Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue (2023 - 2025)

Fennec Pharmaceuticals filings provide 3 years of Non-Current Deffered Revenue readings, the most recent being $24.6 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $24.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.6 million, a 0.0% change, with the full-year FY2025 number at $24.6 million, changed 0.0% from a year prior.
  • Non-Current Deffered Revenue hit $24.6 million in Q4 2025 for Fennec Pharmaceuticals, roughly flat from $24.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $25.0 million in Q1 2024 to a low of $2000.0 in Q4 2023.
  • Median Non-Current Deffered Revenue over the past 3 years was $24.6 million (2024), compared with a mean of $21.9 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: skyrocketed 1227950.0% in 2024 and later decreased 1.73% in 2025.
  • Fennec Pharmaceuticals' Non-Current Deffered Revenue stood at $2000.0 in 2023, then skyrocketed by 1227950.0% to $24.6 million in 2024, then changed by 0.0% to $24.6 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $24.6 million (Q4 2025), $24.6 million (Q3 2025), and $24.6 million (Q2 2025) per Business Quant data.